ADAM 33 gene V4 C/G rs2787094 polymorphism in psoriasis

Creative Commons License

Akcılar R., Namdar N., Koçak F. E., Bayat Z., Burhan H.

Bratislava Medical Journal, vol.119, no.7, pp.454-457, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 119 Issue: 7
  • Publication Date: 2018
  • Doi Number: 10.4149/bll_2018_084
  • Journal Name: Bratislava Medical Journal
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.454-457
  • Keywords: ADAM 33, Psoriasis, V4 C/G gene polymorphism
  • Kütahya Health Sciences University Affiliated: Yes

Abstract

© AEPress s.r.o.AIMS: Psoriasis is a common chronic inflammatory disease. A disintegrin and metalloproteinase 33 (ADAM33) gene is the first novel susceptibility gene for asthma. The aim of this study was to investigate the relationship of ADAM 33 gene V4 C/G rs2787094 polymorphism with the risk of psoriasis in the Turkish population. METHODS: ADAM33 gene polymorphism (V4 C/G rs2787094) was analyzed in 97 psoriasis patients and 50 healthy control subjects. This study was performed by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis. RESULTS: There was no significant difference in ADAM33 genotype and allele distributions between psoriasis and control groups (p > 0.05). CONCLUSIONS: ADAM33 V4 C/G rs2787094 polymorphism was not associated with psoriasis risk in the Turkish population. Larger studies with different ethnicities are needed to determine the impact of ADAM33 polymorphism on the risk of developing psoriasis.